The cuts target J&J’s orthopedics, surgical and cardiovascular device operations. The company has yet to announce plans regarding specific product rollbacks.
Company officials believe the cuts will allow J&J to focus on product innovation and business diversification. “The savings will help us grow our [device] business,” J&J spokesman Ernie Knewitz told Reuters. “That could involve acquisitions, but it will also involve investing in our own internal programs.”
Medical device sales plummeted 10.4 percent within the fist nine months of 2015, making the division J&J’s poorest performing segment.
New Brunswick, N.J.-based J&J employs about 60,000 individuals within its medical devices unit. The job cuts represent almost 6 percent of the division.
The company expects to post fourth quarter results on Jan. 26, according to the article.
More articles on workforce:
Minnesota nurses union, Twin Cities hospitals reach contract deal: 3 things to know
Kadlec Regional, nurses reach tentative contract agreement: 3 things to know
Hospitals and unions: 9 recent conflicts, agreements
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
